Swiss Biotech TECregen Raises $12.56M Seed Round Led by Boehringer Ingelheim Venture Fund
Swiss biotech TECregen announced a CHF 10 million ($12.56 million) seed round, led by Boehringer Ingelheim Venture Fund, to develop thymus‑regenerating biologics. The funding will support the company’s engineered “thymopoietics” platform aimed at rejuvenating thymic epithelial cells.
Boltz Secures $28M Seed Funding to Build Open AI Models in Biology
Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...
French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing
Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.
Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups
French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.
Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools
Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.
Eli Lilly to Acquire Ventyx for $1.2B
Eli Lilly announced it will acquire Ventyx in a $1.2 billion transaction, expanding its neuroscience and immunology pipeline. The deal is driven by Ventyx’s NLRP3 programs with potential applications in pericarditis, Parkinson’s disease, and obesity‑associated cardiometabolic disease.
Crinetics Pharmaceuticals Announces $350M Public Offering
Crinetics Pharmaceuticals announced a $350 million public offering of 7.6 million shares, with an underwriters’ option for an additional $52 million, to fund the development of its atumelnant drug after strong Phase II results that outperformed Neurocrine’s Crenessity. The offering was announced on Monday,...
Amgen to Acquire Dark Blue Therapeutics for Up to $840M
Amgen announced on Tuesday that it will acquire England‑based Dark Blue Therapeutics in a deal valued at up to $840 million, aiming to bolster its oncology pipeline with Dark Blue’s pre‑clinical protein‑degradation assets. The acquisition will integrate Dark Blue into Amgen’s...
Amgen Acquires AML Candidate From UK Biotech Dark Blue
Amgen announced a deal to acquire an acute myeloid leukemia (AML) drug candidate from UK-based biotech Dark Blue. The terms of the transaction were not disclosed. The deal expands Amgen's oncology pipeline.
Nawah Scientific Raises $23M Series A to Expand Cloud Lab Model to Rwanda and Saudi Arabia
Egyptian research platform Nawah Scientific announced a $23 million Series A round, led by Life Ventures Holding with participation from Den Venture, Empire M, AfricInvest and Elsewedy. The funding, a mix of equity and debt, will support the launch of a research...
